Biomimetic platform developed to enhance CAR T cell therapy against leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Ketone supplementation improves immunotherapy outcomes in mice, with human clinical trial underway

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...
Fred Hutchinson Cancer Center

Giving CAR T cells a portable pit crew

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

Engineered CAR-T cells block key protein to break solid tumors' immune shield

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...
The American Journal of Managed Care

CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...